PURPOSE: To evaluate the presence of vascular damage in long-term childhood cancer survivors (CCS) and sibling controls, and to evaluate the association between vascular damage parameters and cancer treatment and influence of cardiovascular risk factors. PATIENTS AND METHODS: Vascular assessment was performed in 277 adult CCSs (median age at diagnosis, 9 years; range, 0 to 20 years; median current age, 28 years; range, 18 to 48 years) treated with potentially cardiovascular toxic anticancer treatment (ie, anthracyclines, platinum, and/or radiotherapy [RT]). Measurements included carotid- and femoral-wall intima-media thickness (IMT), flow-mediated vasodilatation of the brachial artery by ultrasound, assessment of endothelial and inflammatory marker proteins (including tissue-type plasminogen activator [t-PA], plasminogen activator inhibitor type 1 [PAI-I]), and cardiovascular risk factors. CCS assessments were compared with those of 130 sibling controls (median age, 26 years; range, 18 to 51 years). RESULTS: At a median of 18 years (range, 5 to 31 years) after treatment, carotid and femoral IMTs in CCSs were not different from those of controls. However, CCSs who received RT as part of their treatment regimen had increased carotid and femoral IMTs and higher t-PA and PAI-I levels, indicating vascular damage and persistent endothelial activation. Patients treated with RT to the neck or chest also had greater femoral IMT. Greater IMT was associated with presence of cardiovascular risk factors (eg, hypertension and overweight). CONCLUSION: After potentially cardiovascular toxic anticancer treatment, CCSs who received RT showed signs of endothelial damage and an unfavorable cardiovascular risk profile compared with controls. CCSs treated with localized RT had increased IMT outside the primary irradiation field. These abnormalities are probably involved in the pathogenesis of cardiovascular morbidity in CCSs.
PURPOSE: To evaluate the presence of vascular damage in long-term childhood cancer survivors (CCS) and sibling controls, and to evaluate the association between vascular damage parameters and cancer treatment and influence of cardiovascular risk factors. PATIENTS AND METHODS: Vascular assessment was performed in 277 adult CCSs (median age at diagnosis, 9 years; range, 0 to 20 years; median current age, 28 years; range, 18 to 48 years) treated with potentially cardiovascular toxic anticancer treatment (ie, anthracyclines, platinum, and/or radiotherapy [RT]). Measurements included carotid- and femoral-wall intima-media thickness (IMT), flow-mediated vasodilatation of the brachial artery by ultrasound, assessment of endothelial and inflammatory marker proteins (including tissue-type plasminogen activator [t-PA], plasminogen activator inhibitor type 1 [PAI-I]), and cardiovascular risk factors. CCS assessments were compared with those of 130 sibling controls (median age, 26 years; range, 18 to 51 years). RESULTS: At a median of 18 years (range, 5 to 31 years) after treatment, carotid and femoral IMTs in CCSs were not different from those of controls. However, CCSs who received RT as part of their treatment regimen had increased carotid and femoral IMTs and higher t-PA and PAI-I levels, indicating vascular damage and persistent endothelial activation. Patients treated with RT to the neck or chest also had greater femoral IMT. Greater IMT was associated with presence of cardiovascular risk factors (eg, hypertension and overweight). CONCLUSION: After potentially cardiovascular toxic anticancer treatment, CCSs who received RT showed signs of endothelial damage and an unfavorable cardiovascular risk profile compared with controls. CCSs treated with localized RT had increased IMT outside the primary irradiation field. These abnormalities are probably involved in the pathogenesis of cardiovascular morbidity in CCSs.
Authors: Saro H Armenian; Gregory T Armstrong; Gregory Aune; Eric J Chow; Matthew J Ehrhardt; Bonnie Ky; Javid Moslehi; Daniel A Mulrooney; Paul C Nathan; Thomas D Ryan; Helena J van der Pal; Elvira C van Dalen; Leontien C M Kremer Journal: J Clin Oncol Date: 2018-06-06 Impact factor: 44.544
Authors: Saro H Armenian; Wassim Chemaitilly; Marcus Chen; Eric J Chow; Christine N Duncan; Lee W Jones; Michael A Pulsipher; Alan T Remaley; Alicia Rovo; Nina Salooja; Minoo Battiwalla Journal: Biol Blood Marrow Transplant Date: 2016-08-30 Impact factor: 5.742
Authors: Megan E Slater; Julie A Ross; Aaron S Kelly; Donald R Dengel; James S Hodges; Alan R Sinaiko; Antoinette Moran; Jill Lee; Joanna L Perkins; Lisa S Chow; K Scott Baker; Julia Steinberger Journal: Pediatr Blood Cancer Date: 2014-10-18 Impact factor: 3.167
Authors: Cindy K Blair; Aaron S Kelly; Julia Steinberger; Lynn E Eberly; Char Napurski; Kim Robien; Joseph P Neglia; Daniel A Mulrooney; Julie A Ross Journal: Pediatr Blood Cancer Date: 2014-08-30 Impact factor: 3.167
Authors: Merry L Lindsey; Richard A Lange; Helen Parsons; Thomas Andrews; Gregory J Aune Journal: Am J Physiol Heart Circ Physiol Date: 2014-09-12 Impact factor: 4.733
Authors: Eric J Chow; Laura-Mae Baldwin; Anna M Hagen; Melissa M Hudson; Todd M Gibson; Komal Kochar; Aaron McDonald; Paul C Nathan; Karen L Syrjala; Sarah L Taylor; Emily S Tonorezos; Yutaka Yasui; Gregory T Armstrong; Kevin C Oeffinger Journal: Contemp Clin Trials Date: 2019-12-17 Impact factor: 2.226
Authors: Renske Altena; Rudolf S N Fehrmann; Hink Boer; Elisabeth G E de Vries; Coby Meijer; Jourik A Gietema Journal: PLoS One Date: 2015-01-15 Impact factor: 3.240